Oncolinx is developing the next generation of antibody-drug conjugates (ADCs)--powerful, targeted cancer therapies that are more effective and have dramatically fewer side effects than current methods of cancer treatment. These therapies can be targeted to nearly any type of cancer and are rapidly becoming the state-of-the-art in cancer treatment. Drawing on the scientific innovation of the National Cancer Institute, the world's leading biotechs and life sciences companies, Oncolinx is redefining the paradigm of cancer therapy.
View Top Employees from Oncolinx| Website | http://www.oncolinx.com/ |
| Revenue | $1 million |
| Employees | 4 (1 on RocketReach) |
| Founded | 2013 |
| Address | 640 Ellicott St, Ste 108, Buffalo, New York 14203, US |
| Phone | +44 20 3514 1013 |
| Technologies |
JavaScript,
HTML,
Twitter
+4 more
(view full list)
|
| Industry | Biotechnology Research, Venture Capital & Private Equity, Biotechnology, Finance, Science and Engineering, Health Care, Medical |
| Competitors | Medicago, Minoryx Therapeutics, Protalix Biotherapeutics, SQZ Biotechnologies, iBio, Inc. |
| SIC | SIC Code 87 Companies, SIC Code 873 Companies |
| NAICS | NAICS Code 541714 Companies, NAICS Code 54 Companies, NAICS Code 541 Companies, NAICS Code 54171 Companies, NAICS Code 5417 Companies |
Looking for a particular Oncolinx employee's phone or email?
Oncolinx Questions
The Oncolinx annual revenue was $1 million in 2023.
1 people are employed at Oncolinx.
Oncolinx is based in Buffalo, New York.
The NAICS codes for Oncolinx are [541714, 54, 541, 54171, 5417].
The SIC codes for Oncolinx are [87, 873].
Related Companies
